Safety and efficacy of insulin detemir versus NPH in the treatment of diabetes during pregnancy: Systematic review and meta-analysis of randomized controlled trials

Athanasiadou, Kleoniki I.; Paschou, Stavroula Α.; Stamatopoulos, Theodosios; Παπακωνσταντίνου, Ευγενία; Haidich, Anna‐Bettina; Goulis, Dimitrios G.

doi:10.1016/j.diabres.2022.110020

Cited by 7 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acylace poskytuje prodloužený farmakokinetický a farmakodynamický profil, což vede ke snížené fluktuaci koncentrace glukosy v krevní plasmě. Insulin Detemir byl schválen FDA v roce 2005 je využíván k léčbě T1DM a T2DM s využitím injekčního pera 63,64 .…”

Section: Komerčně Dostupné Lipopeptidyunclassified

Lipidization as a Tool for Peptide Drug Development

Myšková,

Sýkora,

Kuneš

et al. 2024

Chem. Listy

View full text Add to dashboard Cite

Peptide therapeutics are becoming increasingly important in the quest for effective compounds to treat various difficult-to-cure diseases. As potential therapeutics, peptides have many favorable chemical and pharmacological properties, ranging from their great diversity to their high affinity to various types of natural receptors. However, despite these and other advantages, they also have their pitfalls, such as a very limited stability in the organism. They have a short half-life and tend to be excreted from the body very quickly. In order to achieve a better pharmacological effect, it is desirable to find new means of modifying peptides to enable them to be used as effective drugs. There are many ways of altering the peptide structure. In this review, we summarize the approaches currently used to modify the peptide constitution with a focus on lipidization. Simultaneously this review summarizes all lipidized peptide-based therapeutics that are currently on the market.

show abstract

Section: Komerčně Dostupné Lipopeptidyunclassified

Lipidization as a Tool for Peptide Drug Development

Myšková,

Sýkora,

Kuneš

et al. 2024

Chem. Listy

View full text Add to dashboard Cite

show abstract

“…In a meta-analysis of randomized, controlled trials that compared detemir to neutral protamine Hagedorn (NPH) insulin, detemir was associated with fewer maternal hypoglycemic events and decreased risk of prematurity. Another multicenter, prospective cohort compared detemir to other basal insulins including NPH in pregnant women with pre-existing diabetes and found no difference in efficacy and safety [104,105]. The recently published EXPECT trial found degludec to be non-inferior to detemir, while data on glargine is mostly observational and requires further investigation [106].…”

Section: Pharmacotherapy In Pregnancymentioning

confidence: 99%

Drug Therapies for Diabetes

Weinberg Sibony,

Segev,

Dor

et al. 2023

IJMS

View full text Add to dashboard Cite

The treatment of type 2 diabetes (T2D) necessitates a multifaceted approach that combines behavioral and pharmacological interventions to mitigate complications and sustain a high quality of life. Treatment encompasses the management of glucose levels, weight, cardiovascular risk factors, comorbidities, and associated complications through medication and lifestyle adjustments. Metformin, a standard in diabetes management, continues to serve as the primary, first-line oral treatment across all age groups due to its efficacy, versatility in combination therapy, and cost-effectiveness. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) offer notable benefits for HbA1c and weight reduction, with significant cardiovascular benefits. Sodium-glucose cotransporter inhibitors (SGLT-2i) lower glucose levels independently of insulin while conferring notable benefits for cardiovascular, renal, and heart-failure outcomes. Combined therapies emphasizing early and sustained glycemic control are promising options for diabetes management. As insulin therapy remains pivotal, metformin and non-insulin agents such as GLP-1 RA and SGLT-2i offer compelling options. Notably, exciting novel treatments like the dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) agonist show promise for substantially reducing glycated hemoglobin and body weight. This comprehensive review highlights the evolving landscape of pharmacotherapy in diabetes, the drugs currently available for treating diabetes, their effectiveness and efficacy, the impact on target organs, and side effects. This work also provides insights that can support the customization of treatment strategies.

show abstract

“…Detemir has a prolonged half-life in comparison with neutral Protamine Hagedorn (NPH) insulin (Novolin N/Humulin N, Novo Nordisk) also known as isophane insulin. Acylated insulin shows a stable pharmacokinetic and pharmacodynamic profile, meaning that it causes lesser and less frequent fluctuations of the mean plasma glucose concentration and fewer overall hypoglycemic events than NPH insulin (Athanasiadou et al., 2022 ). Insulin detemir is prescribed to treat T1DM and T2DM, and it has been approved by the FDA since June 2005.…”

Section: Lipidized Drugs On the Marketmentioning

confidence: 99%

Lipidization as a tool toward peptide therapeutics

Myšková,

Sýkora,

Kuneš

et al. 2023

Drug Delivery

View full text Add to dashboard Cite

Peptides, as potential therapeutics continue to gain importance in the search for active substances for the treatment of numerous human diseases, some of which are, to this day, incurable. As potential therapeutic drugs, peptides have many favorable chemical and pharmacological properties, starting with their great diversity, through their high affinity for binding to all sort of natural receptors, and ending with the various pathways of their breakdown, which produces nothing but amino acids that are nontoxic to the body. Despite these and other advantages, however, they also have their pitfalls. One of these disadvantages is the very low stability of natural peptides. They have a short half-life and tend to be cleared from the organism very quickly. Their instability in the gastrointestinal tract, makes it impossible to administer peptidic drugs orally. To achieve the best pharmacologic effect, it is desirable to look for ways of modifying peptides that enable the use of these substances as pharmaceuticals. There are many ways to modify peptides. Herein we summarize the approaches that are currently in use, including lipidization, PEGylation, glycosylation and others, focusing on lipidization. We describe how individual types of lipidization are achieved and describe their advantages and drawbacks. Peptide modifications are performed with the goal of reaching a longer half-life, reducing immunogenicity and improving bioavailability. In the case of neuropeptides, lipidization aids their activity in the central nervous system after the peripheral administration. At the end of our review, we summarize all lipidized peptide-based drugs that are currently on the market.

show abstract

Safety and efficacy of insulin detemir versus NPH in the treatment of diabetes during pregnancy: Systematic review and meta-analysis of randomized controlled trials

Cited by 7 publications

References 37 publications

Lipidization as a Tool for Peptide Drug Development

Lipidization as a Tool for Peptide Drug Development

Drug Therapies for Diabetes

Lipidization as a tool toward peptide therapeutics

Contact Info

Product

Resources

About